

October 5, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)
Contact: Richard Kincaid, Executive Officer CFO
(TEL: 03-6807-5937)

Shipment and Revenue Recognition of Initial Order of Culture Supernatant Products to JENECELL

HEALIOS K.K. (“Healios”) is engaged in business activities aimed at developing and providing innovative therapies and products in the field of regenerative medicine. As part of these efforts, we are advancing the research, development, manufacturing, and sales of products based on somatic stem cell culture supernatant.

As announced on September 30, 2026 in “[Notice Regarding Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL](#)”, Healios had provided notice of the scheduled timing of its shipment of culture supernatant to be used as a raw material for cosmetics (the "Product") to JENECELL (Head office: 397 Seochodae-ro #A-1907, Seocho-gu, Seoul, 06616, South Korea (<https://www.jenecell.com>)); “JENECELL”).

Healios is pleased to announce that it has completed the shipment of the Product for the initial order, worth approximately 144 million yen, to JENECELL, and has recognized the related revenue. This shipment represents Healios's first commercial shipment of products based on its cell culture supernatant platform, marking a concrete step toward capturing an additional revenue stream alongside its regenerative medicine pipeline.

Regarding future continued orders, Healios will continue to discuss the shipment volume and timing of the Product with JENECELL. Culture supernatant is expected to have applications across a wide range of fields, including pharmaceuticals and cosmetics. Healios will continue to build relationships with, and hold discussions with, multiple promising business partners regarding the research and sales of applications for culture supernatant.

Future Outlook

This revenue will be recognized in the fourth quarter of the fiscal year ending December 2026. If any matters that should be disclosed arise in the future, we will announce them promptly.

About JENECELL:

JENECELL is a South Korean subsidiary of Alfresa Corporation, a subsidiary of Alfresa Holdings Corporation—the leading pharmaceutical wholesaler in Japan—and develops innovative products utilizing cutting-edge technology across a wide range of fields, including stem cell-based pharmaceuticals, medical devices, and cosmetics. In particular, we are driving the development of high-performance skincare products through our premium cosmetics business, which is based on stem cell-conditioned media (MSC-CM). Building on strategic partnerships with promising South Korean biotech and healthcare companies, we are actively pursuing an open innovation strategy that includes both In and Out business initiatives as well as mergers and acquisitions.

<https://www.jenecell.com>

About Healios:

HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>